

**Establishing an open access, environmentally controlled  
Compound Management facility in Australia**

Author

Camp, David

Published

2008

Conference Title

Establishing an open access, environmentally controlled Compound Management facility in  
Australia

Downloaded from

<http://hdl.handle.net/10072/20521>

Link to published version

<http://www.iqpc.events.com/ShowEvent.aspx?id=45654>

Griffith Research Online

<https://research-repository.griffith.edu.au>

"Excellent balance of large & small pharmas, world experts and appropriate vendors - a great networking opportunity" Pfizer

pharma IQ  
a division of IQPC

Pharma IQ's 5th Annual

# Compound Management & Integrity 2008

## CM 2008 Keynote Speaker:



**Dr. Ricardo Macarron**,  
Vice President of  
Compound Management,  
GlaxoSmithKline &  
President of the SBS

Benefit from **30+** sessions,  
including case studies and  
presentations from:



**Dr. Timo Flessner**, Director,  
Head of Medicinal Chemistry 5,  
Bayer Schering Pharma



**Dr. Terry Wood**, Head of Liquid  
Store Centre of Emphasis,  
Pfizer Global R&D



**Gwendolyn Goedbloed**,  
Associate Director, Virology  
Laboratory Operations,  
Tibotec BVBA



**Dr. Janet Cheetham**,  
Executive Director  
Amgen



**Dr. David Camp**, Director, Eskitis  
Institute for Cell & Molecular  
Therapies,  
Griffith University



**Kimberly A. Matus**, Associate  
Director, Discovery Chemistry  
Sourcing,  
Pfizer Global R&D



**Dr. Wolfgang Roeben**, Head of  
Global Logistics,  
Bayer CropScience AG



**Dr. Snehal Bhatt**, Manager,  
Automatic Liquid Store,  
GlaxoSmithKline



**Dr. Ingo Muckenschnabel**,  
Laboratory Head, Analytics,  
Novartis Pharma AG

## CM 2008 Sponsors



INTERFACES – PERFORMANCE – QC – AUTOMATION

20<sup>th</sup> - 22<sup>nd</sup> May 2008 – Thistle Marble Arch, London

CM 2008 promises to deliver comprehensive coverage on the most current thinking, practices and technology in CM.

You will take home how to:

- **Drive** your company's drug discovery success by ensuring quality processes from Compound Management, into Medicinal Chemistry decisions and out of Focused Screening
- **Utilise** the latest analytical characterisation technology to generate valuable QC data to incorporate into lead discovery decision making
- **Implement** low-volume liquid handling and modern automation techniques to improve efficiency and accuracy of your compound handling
- **Successfully** transport compounds globally and utilise outsourcing options to improve efficiency and flexibility – **Don't miss Pfizer's session on their decision to outsource their neat sample bank**
- **Adapt** the CM role to meet the needs of evolving hit discovery tactics to ensure smooth and successful operations

Limited offer to  
first 20 registrations  
– SAVE up to  
£1000!

## \*New for CM 2008\*

- ✓ Exclusive Focus Day on **How to Improve the Critical Interface and Workflow between CM, Screening & Research Teams** – learn how you can contribute to this key growth opportunity in your company
- ✓ Build relationships at the pre-conference Welcome Drinks, in addition to the structured Networking Reception and announcement of the 'Compound Manager of 2008' award winner
- ✓ Access and network with delegates of the **Lead-Finding Screening 2008** conference during joint roundtable discussions, networking occasions, workshops and the Focus Day on Interfaces
- ✓ Pre-conference interactive workshop on **Closing the gap - Integration of Compound Management with High Throughput Screening data management systems and LIMS**

## How to Improve the Critical Interface and Workflow between CM, Screening &amp; Research Teams

- 10.00 Opening Remarks from Chairperson  
**Outlining expected outcomes of the Focus Day and active role of each person taking part**  
*This Focus Day will be used to understand the varying needs of each department and to establish workable solutions toward more stable workloads, optimised, efficient processes from store to screen, and how we can contribute to lead discovery success.*  
 **Terry Wood**, Head of Liquid Store Centre of Emphasis, **Pfizer Global R&D**
- 10.10 **Breakout Brainstorming Sessions**  
**Understanding and defining the limitations and expectations of each department**  
 Screeners, Compound Managers & Project leaders will break into three groups to lay out what their expectations are for their colleagues; how they feel the other team can work more in-line with their requirements; and devise some workable suggestions for improvement. Suggestions will be written out on white-boards for discussion points in this afternoon's group discussion.
- 11.00 **CM Perspective: Opportunities and realistic cooperative efforts – how we can work together to contribute to lead discovery success**  
  - Current challenges and the successful steps we've taken to overcome them
  - Examples of how improved quality compounds are becoming more lead-like hits
  - Discussing the level of cooperation and changes that need to occur to ensure efficient operations between teams
  - Tools and processes we can work together to implement to increase efficiency of molecules going thru lead discovery
  - Future directions and goals of how we can contribute to speeding up R&D **Janet Cheetham**, Executive Director, **Amgen**
- 11.40 **Screening Perspective: Absolute necessities and how CM can contribute to successful screening**  
  - Rolling with the changes - With technology and assay approaches advancing, so do the expectations on CM
  - Describing where and how we see opportunities in process efficiencies
  - Taking a collaborative approach with our CM team
  - The new UK CM system – how we expect operations to develop and improve
  - Bottom line – what we need from CM and research teams to make our job easier, and more successful**Jenny Stables**, Head of Cellular HTS, **GlaxoSmithKline**
- 12.20 Lunch
- 13.20 **hERG, a Cardiac Safety Assay Case Study: Leveraging Organon's new IT infrastructure to standardise assays, track compounds and improve the overall quality process and workflows from store – site – screen**  
  - Establishing one streamlined, integrated workflow with Medicinal Chemistry
  - Deciding on and implementing software to standardise assay formats
  - Using examples to demonstrate how a bar-coded system helps monitor quality and enables full trackability to know what exactly is being screened
  - Demonstrating how efficiency was gained in the hERG case study with the integrated quality processes **Sylviane Komesli**, Section Head Molecular Pharmacology, **Organon**, a part of Schering-Plough Corporation
- 14.00 **Building a u-HTS system to be integrated with Genentech's new CM store for smooth and efficient advanced screening**  
  - Advancing Genentech's small molecule R&D by developing a u-HTS system for rapid screening
  - Offering high quality service and reliable automation to any research team conducting assays
  - Future expectations of the impact of the integrated u-HTS and CM store to Genentech's business **Tim Dawes**, Sr. Scientific Manager, Early Leads, **Genentech**
- 14.40 Coffee Break
- 15.00 **AstraZeneca's new thinking: Developing a more direct process and defined workflow**  
  - Recent initiatives to improve our relationship with CM and the importance interface into screening
  - How we are establishing more direct processes from storage to screening
  - Implementing an efficient screening system that CM can access and use
  - Discussing an agreeable turnaround time for assay ready plates - how can we maximise the value of this method?**Dr. Eric Tang**, Director, Oncology Automation Screening Support Team, **AstraZeneca**
- 15.40 **Defining best practice interface opportunities & Examining the impact of our efforts on lead discovery**  
  - Key points and remaining issues from this morning's breakout sessions
  - Key take-away lessons to improve critical interfaces in your lead discovery
  - Measuring our integration efforts impact:
    - Have hits and subsequently SARs increased due to quality of compounds going into screening?
    - Have the number of lead optimisation projects increased due to higher quality processes being implemented by CM and Screening?**Panelists:**  
 **Ricardo Macarron**, Ph.D., Vice President of Compound Management, **GlaxoSmithKline & President of the SBS**  
 **Janet Cheetham**, Executive Director, **Amgen**  
 **Sylviane Komesli**, Section Head Molecular Pharmacology, **Organon**, a part of Schering-Plough Corporation  
**Dr. Eric Tang**, Director, Oncology Automation Screening Support Team, **AstraZeneca**  
**Jenny Stables**, Head of HTS, **GlaxoSmithKline**  
 **Terry Wood**, Head of Liquid Store Centre of Emphasis, **Pfizer Global R&D**
- GROUP DISCUSSION**
- 16.20 **Conclusions and closing remarks**

Pre-Conference Workshop: 20<sup>th</sup> May 2008

16.30 -19.30

## Closing the gap - Integration of Compound Management with High Throughput Screening data management systems and LIMS

High throughput screening (HTS) is no longer the bottle neck in drug discovery; thousands of data points can be screened in many target assays resulting in mountains of data to analyse. Compound Management groups have answered this increased capacity by automating sample storage, retrieval and plate replication resulting in the ability to provide thousands of compounds in a variety of plate formats to HTS groups.

However key challenges remain; the right screening result must be associated with the right compound ID. Compound management systems do not always integrate with assay management systems or LIMS systems resulting in

reduced cycle time; slowing down the process of hit follow up and lead identification. This workshop will explore challenges like this, and examine different options for integrating the physical movement of samples and plates from automated systems with virtual data management systems to ensure the correct assay result is associated with the correct compound ID. The interactive discussion forum will examine:

- Case studies on how VWorks integrates with custom or commercial LIMS systems through an open architecture and exposed API
  - Informatics interface challenges between Compound Management and HTS groups
- Workshop Leader: **Velocity 11**

## CM 2008 Welcome Drinks Reception &amp; Networking Opportunity

From 19.00 - Take the time after today's Focus Day and workshop to relax before the conference, meet up with familiar faces again and enjoy informal networking with your industry colleagues.



8.15 Registration and Coffee

9.00 **Pharma IQ Welcome**9.05 **Chairperson Opening Remarks****Christine Rigby**, Associate Director, Global Compound Sciences, **AstraZeneca**9.15 **Drug Discovery today: Compound Management's role in a stressed environment**

- Challenges of Drug Discovery today
- Evolution of hit discovery tactics and their impact on CM
- Role of CM in adapting to changes and contributing to lead discovery success
- Valuable lessons in improving the quality processes from store to screen
- Responding to the current environment by improving the quality of CM operations and corporate compound collections

**Ricardo Macarron**, Ph.D., Vice President of Compound Management, **GlaxoSmithKline & President of the SBS**10.00 **The Management of Compound Management: How to get buy in for CM**

- Managing change in the collaborative role of CM in the drug discovery organisation – how can we be most flexible in our integrated role?

- Responding to new requirements and trends in target based screening

- The secret to success of managing a CM team
- Steps on how to demonstrate the value of CM to key partners

**Terry Wood**, Head of Liquid Store Centre of Emphasis, **Pfizer Global R&D**

10.30 Morning refreshments

11.00 **Global Challenges in Compound Management; Optimising workflows, improving customer service and contributing to the overall performance of Drug Discovery**

Over the last decade many companies have made large investments in Compound Management storage, 'high tech' automated robotic systems, low volume liquid handling and analytical characterisation technology. Leadership of AstraZeneca's global CM task force across 9 sites has given insight of the challenges that large Pharma face including:

- The benefits of a highly motivated global CM Network
- Streamlining processes and optimising performance at the global level
- Maximising return on local and global investments - Delivering New capabilities
- Ensuring customer focused delivery and establishing global service level agreements
- Understanding risk and managing costs
- Ensuring global synergies

**Christine Rigby**, Associate Director, Global Compound Sciences, **AstraZeneca**11.45 **Establishing an open access, environmentally controlled Compound Management facility in Australia**

- Evaluation factors for choosing a system configuration consisting of three main building blocks (microtube store, sample processing unit and microplate store)
- How we intend to preserve sample integrity for extended (5-6 years) periods of time
- Implementing environmentally controlled plate and tube storage with sample processing to ensure that compound integrity is maintained without compromising flexibility
- Facilitating collaborations between different groups of scientists by leveraging a unique IP model, current HTS infrastructure and the new fully integrated compound handling system
- A view to the future – adopting this modular approach allows future capacity building and throughput increases to be realised with minimal disruption to on-going operations

**Dr. David Camp**, Director, Eskitis Institute for Cell & Molecular Therapies, **Griffith University**

12.30 Lunch and Networking time in Exhibition

13.45 **Discovering small molecules at Tibotec: Automated anti HIV drug screening platform at a medium-size pharmaceutical company**

- Storing test compounds in DMSO solutions in an automated storage system with optimised environmental conditions
- Using automated cell-based assay with fluorescent read-out on a laser microscope to investigate anti-HIV activity
- Working with a nano-liter liquid handling device for primary screening and transferring compound libraries into assay plates

**Gwendolyn Goedbloed**, Associate Director, Virology Laboratory Operations, **Tibotec BVBA**14.30 **Generating valuable QC data and utilising it in lead discovery decision making**

- Providing real-time information on an open access system to Medicinal Chemists
- Throughput vs. quality: Describing the correlation of low throughput data vs. high throughput data
- Different data for different folks – discussing the varying perceived value of data
- Making a positive overall impact on drug discovery with QC efforts
- A look at progress made with acoustic technology

**Dr. John Eschelbach**, Scientist, Discovery Analytical Sciences, **Amgen**15.15 **Does Modern Medicinal Chemistry incorporate the valuable QC purity and concentration data to decide what to screen – could we have a positive impact on attrition?**

- Using valuable data to stay in a competitive market to produce viable drug leads, candidates and products
- Transferring 'knowledge' of compounds into decisions on which compounds to screen
- Discussing best approaches to growing and developing optimal QC stock and a results-based library

*Today's speakers and delegates are invited to join this discussion*

16.00 Afternoon refreshments

16.30 During each roundtable, the facilitator will present a short case study as a benchmark for a 60 minute discussion and question session. Attendees will get a comprehensive review of the surrounding issues, technical capabilities and differing end-user views. You will also get answers to many questions and new innovative ideas to take back and apply to your compound management work.

**\*\*Delegates are welcome and encouraged to bring their own data or study results to contribute to the discussion and get feedback from the group.****A) Analytical Methods in CM – strengths and weaknesses for high throughput NMR as qualitative and quantitative analytic method**Roundtable Leader: **Dr. Till Kühn**, Product Manager, **Bruker BioSpin AG****B) Evaluating technology available for low volume liquid handling and evaluating cost vs. benefit**Roundtable Leader: **Dr. Eric Tang**, Director, Oncology Automation Screening Support Team, **AstraZeneca****C) Collection lifecycle – Discussing best practices re-stocking, updating a successful compound library****D) Comparing available technologies for automated use of 1536 compound storage plates with and their impact on CM and Screening operations**Roundtable Leader: **Claude Dufresne**, Senior Investigator, **Merck Research Laboratories****E) CM / Screening interface challenges: Key lessons to improving processes store to screen**17.30 **Summary of stimulating roundtable discussions**18.00 **Close of Day One**18.00 **Structured Networking Drinks Reception for both CM and Screening conference delegates**



Join your peers in Compound Management, Screening, Lead Discovery / Finding, and Medicinal and Analytical Chemistry to catch up on the latest industry news and take part in, what we like to call, 'Cross Networking'.

Cross Networking brings together the right people across different functions in an organisation, that can collaborate, network to have a positive, successful impact on their contribution to their company.




Participants will be invited to take part in the 'Solve the Riddles' networking game. The grand prize winner will receive a Waterproof Digital Camera.

**Announcement of the 'COMPOUND MANAGER OF 2008' Award**Part of advancing the science of CM is promoting key contributors in the field. Take this opportunity to recognise your colleague's significant contributions to CM. Nominate them at [www.compoundmanager.com](http://www.compoundmanager.com)

- 8.15 Coffee and Networking in Exhibition
- 8.50 Opening remarks from Chairperson
- 9.00 **Pfizer's decision to outsource the neat sample library**
- Expected gains of outsourcing our solid sample collection: Flexibility and efficiency
  - Additional gains of outsourcing: Equally high service levels and enabling a greater focus on our core business of drug discovery
  - Discovery research vs. service mentality: Who does what best?
  - Full trackability from cradle to grave: How we know where all compounds are at all times
  - Meeting customer satisfaction and managing resources
-  **Kimberly A. Matus**, Associate Director, Discovery Chemistry Sourcing, **Pfizer Global R&D**
- 9.45 **Working with outsourcing partners to achieve efficient and cost-effective CM operations**
- Balancing internal strengths with external partner's expertise
  - Choosing the right partner
  - Challenges in setting up and managing a business relationship
  - Examples of successful outsourcing in sample management and compound acquisition
-  **Eva-Maria Gutknecht**, Head of Compound Management, **F.Hoffmann-La Roche**
- 10.30 Morning Coffee Break
- 11.00 **Global logistical challenges in the chemical compound supply chains, Cross-Border Transportation and regulatory compliances**
- Shipping chemical compounds world-wide – Outlining the key

- challenges in Cross-Border Transportation and Compliance
- Working with and educating the various regulatory agencies and custom officials to interpret and implement new US laws
- Training and awareness of employees to overcome common local challenges, record retention, metrics gathering, compound valuation and potential custom audits
- Utilising new software to standardise processes and to enable internal controls
- Case Study - Key lessons learned that have reduced transit time and custom delays
- Global acquisition of compounds: Challenges, concerns, and cultural assessment of chemical samples between countries
- Knowing how to handle controlled substances during transportation of compounds

 **Dr. Snehal Bhatt**, Manager, Automatic Liquid Store, **GlaxoSmithKline**




- 11.45 **Bayer Schering Pharma - Integration of CM and chemical discovery processes post-acquisition: Building unified single processes for efficient and productive operations**
- Post-acquisition challenges: Identifying the key barriers ahead and how we intend to overcome them
  - Working toward harmonised processes and clear responsibilities to optimally supply scientists globally
  - Narrowing the gap between chemistry, biology and CM mind-sets: How we are working toward one common goal
-  **Dr. Timo Flessner**, Director, Head of Medicinal Chemistry 5, **Bayer Schering Pharma**

12.30 Lunch

#### TRACK A: QC & ANALYTICAL CHARACTERISATION

- 13.30 **A proactive approach to monitoring and tracking compound quality assurance**
- Current QC challenges managing compound collections
  - Best practice technology and data use
  - Creating and sustaining a high quality screening collection as an essential component to producing high quality drug discovery data
  - Meeting the significant challenges in a high throughput environment with tight timelines
  - Reviewing the options available, benefits and drawbacks and techniques employed at AstraZeneca
-  **Isabel Charles**, Associate Principle Scientist, Global Compound Sciences, **AstraZeneca**
- 14.15 **QC follow-up process: Grouping and assessing compounds to ensure maximum quality and downstream success**
- Deciding the best approaches to categorise and share valuable QC data
  - Grouping compounds based on several parameters to ensure information is easily accessed and utilised
  - Reducing cost and the number of screens by weeding out poor quality compounds before screening
  - Giving examples of how the QC follow up process at Novartis is helping improve downstream lead discovery
-  **Dr. Ingo Muckenschabel**, Laboratory Head, Analytics, **Novartis Pharma AG**
- 15.00 Afternoon Refreshments
- 15.30 **Case Study: Compound identity, purity and concentration - the challenges of confirming the third dimension of sample quality using CAD detection**
- Evaluating the use of CAD detection as a solution for measuring compound concentration
  - Using this additional indicator of compound quality to benefit data interpretation for both low and high throughput assays
  - Assessing the reliability of the CAD system
  - Illustrating precision and accuracy of measurements through examples
-  **Ian Sinclair**, QA Specialist, Global Compound Sciences, **AstraZeneca**
- 16.15 **COMDECOM: Predicting COMpound DECOMposition in DMSO solution**
- The COMDECOM dataset is generated of 15,000 compounds selected by seven pharmaceutical companies
  - Monitoring stability in accelerated thermal, hydrolytic and oxidative decomposition testing
  - The predictive model: Development of an algorithm to flag compounds that are likely to decompose and therefore saving valuable resources
-  **Dr. Emrin Zitha-Bovens**, Manager Quality Control, Specs
- 17.00 Closing remarks and end of conference

#### TRACK B: AUTOMATION FROM STORE TO SCREEN

- 13.30 **Implementing 100% DMSO workflows and nanolitre liquid handling at the Pfizer HTS Centre of Emphasis**
-  **Joe Bradley**, HTS Centre of Emphasis, **Pfizer**
- 14.15 **Acoustic case study: AstraZeneca technology application and results**
- Assessment of current acoustic technology available – have we found a HT instrument?
  - Practical implementation of acoustic technology – describing the barriers overcome to get up and running
  - Acoustic dispensing & acoustic mixing – a dynamic duo excelling our compound and screening operations
  - Best practices using the technology
  - Future directions
- Karen Roberts**, Automation Specialist, **AstraZeneca**
- 15.00 Afternoon Refreshments
- 15.30 **Optimising plate storage formats to streamline focused libraries screening: Automated use of lidded 1536 storage plates**
- Assessing automated solutions for 1536 storage plate handling: Limitations and positive aspects
  - Describing the evaluation and use of new lid designs, paired with acoustic dispensing compatible plates
  - Increasing the rapid availability of various screening modalities to a wider range of targets
  - Using examples to demonstrate how this concept is improving the implementation of the integrated 'store and screen' paradigm
-  **Claude Dufresne**, Senior Investigator, **Merck Research Laboratories**
- 16.15 **Case Study: Streamlining the workflow from bottle to plate with a fully integrated HT system for compound handling and screening**
- Choosing the technology and establishing the system for one streamlined workflow
  - Total automation from storage to screening
  - How our streamlined workflow contributes to successful screening and making our biology colleagues happy
  - Extending capacity of CM facilities to meet the increasing demands of our drug discovery efforts
-  **Dr. Wolfgang Roeben**, Head of Global Logistics, **Bayer CropScience AG**
- 17.00 Closing remarks and end of conference

**"Great as usual - best place to have face-to-face conversations with leaders in the CM community"**

GlaxoSmithKline

**Session Sponsors**



**Telephone:** +44 (0)1763 262626  
**Fax:** +44 (0)1763 261964  
**E-Mail:** sales@ttplabtech.com  
**Website:** www.ttplabtech.com



**Telephone:** +31 15 2518111  
**Fax:** +31 15 2518181  
**E-Mail:** info@specs.net  
**Website:** www.specs.net

**Delegate Package Sponsor**



**Telephone:** +41 31 770 70 70  
**Fax:** +41 31 770 72 66  
**E-mail:** info@remp.com  
**Website:** www.remp.com

**Roundtable Sponsor**



**Telephone:** +41 44 825'91'11  
**Fax:** +41 44 825'96'96  
**E-Mail:** sales@bruker-biospin.ch  
**Website:** www.bruker.com

**Featured Exhibitors**



**Telephone:** +44 (0) 1992 470757  
**Fax:** +44 (0) 8700 511302  
**E-mail:** info@KBioscience.co.uk  
**Website:** www.kbioscience.co.uk



**Telephone:** +44 (0)20 7367 6869  
**Fax:** +44 (0)20 7367 6868  
**E-mail:** info@titian.co.uk  
**Website:** www.titian.co.uk



**Telephone:** +1 858 679 0770  
**Fax:** +1 858 679 1260  
**E-mail:** sales@nexusbio.com  
**Website:** www.nexusbio.com



**Telephone:** +44(0) 161 777 2000  
**Fax:** +44(0) 161 777 2003  
**Website:** www.rts-group.com



**Telephone:** +44 (0) 1829 771244  
**Fax:** +44 (0) 1244 560219  
**Website:** www.hireseng.com



**Telephone:** +1 (508) 544-7000  
**Fax:** + (508) 544-70001  
**Website:** www.hamilton-storage.com

**Sponsorship Opportunities**

Compound Management & Integrity 2008 will provide the perfect platform for CM automation, informatics, sample processing and analytical technology providers to demonstrate their offerings to potential clients. From our research, we understand that drug discovery organisations throughout Europe are looking for more stable, robust technologies to help measure and improve their compound identity, purity and quantity. Senior-level delegates are also interested in improving automation efficiency and establishing easy-to-use informatics infrastructures. Join us at CM 2008 to explore the technical CM needs of drug discovery companies in Europe and develop new business relationships. For more information on Sponsorship or Exhibition Opportunities, please call Gal Cohen on +44 (0)20 7368 9491 or email gal.cohen@iqpc.co.uk

**New Conference Co-location – Lead-Finding Screening 2008**



Pharma IQ's **Lead-Finding Screening 2008** conference will compare new approaches and quality processes for flexible, focused lead-finding screening and lead optimisation methods. Delegates will review results of several case studies to learn what alternative screening decisions and investments have been justified. Delegates will use this valuable insight to assess which new screening approaches work for their targets and company strategy. Please visit [www.iqpc.com/uk/screening](http://www.iqpc.com/uk/screening) for more details.

The co-location of **Lead-Finding Screening 2008** will provide joint roundtable discussions, networking opportunities and workshops to facilitate exchange of ideas between adjacent colleagues in CM, Screening and Research Teams.

Don't miss the Focus Day.... (see agenda page 2) to assess the varying needs of each department and to establish workable solutions toward more stable workloads, optimised, efficient processes from store to screen, and how collaborations can contribute to lead discovery success.

**JOIN THE CONFERENCE AS A TEAM**

Pharma IQ recognises the value of learning in teams. Maximise your conference networking opportunities and ensure an integrated approach is taken to apply new learnings when you return to the office. See back page for team discount details.

*"Most valuable conference for CM. Excellent presentations, good networking as a source of new ideas for implementation"* F. Hoffman La Roche

*"Great speaker panel covering a variety of issues. As always a good meeting where the whole compound management family is present, keep up the good work."*

Specs

*"A good mix between several comp. A good conference, very focussed on issues that I deal with on a daily basis. Good to hear that almost everyone is dealing with the same issues."* Biovitrum AB

*"Overall it's a great composition of speakers. This is one of the most interesting/enjoyable events."* AstraZeneca

**Media Partners**



# Compound Management & Integrity 2008

20th - 22nd May 2008 – Thistle Marble Arch, London

## REGISTRATION FORM

To speed registration, please provide the priority code located on the mailing label or in the box below.

My registration code is

**S**

Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to inform us of any changes or to remove your details.



Web: [www.compoundmanager.com](http://www.compoundmanager.com)



Phone: +44 (0) 20 7368 9300



Fax: +44 (0) 20 7368 9301



Email: [enquire@iqpc.co.uk](mailto:enquire@iqpc.co.uk)



Post: IQPC Ltd. Anchor House,  
15-19 Britten Street,  
London, SW3 3QL, UK

## Team Discounts

IQPC recognises the value of learning in teams. Groups of 3 or more booking at the same time from the same company receive a 10% discount. 5 or more receive a 15% discount. 7 receive a 20% discount. Only one discount available per person.

## Venue & Accommodation

**VENUE:** Thistle Marble Arch Hotel  
Bryanston Street, Marble Arch,  
Central London, W1H 7EH  
Tel: 0870 333 9116 Fax: 0870 333 9216  
Email: [MarbleArch@Thistle.co.uk](mailto:MarbleArch@Thistle.co.uk)

**ACCOMMODATION:** Hotel accommodation and travel costs are not included in the registration fee. A preferred rate has been negotiated of **£125 + VAT per night. Please call the hotel directly on +44 (0)870 41 41 516 and always quote 'GA2' when booking.** For further selection of local hotels, please search [www.cityhotelaccommodation.com](http://www.cityhotelaccommodation.com). It is advisable to book early to secure the reduced rate.

**Thistle Marble Arch** is just a walk or short taxi ride from the busy streets of Covent Garden and the theatrical excitement of Shaftsbury Avenue - here you will find the spacious and relaxed ambience of this London hotel. Overlooking Oxford Street, this hotel occupies an unrivalled position from which to enjoy London's unique attractions. This art-deco style hotel features 692 bedrooms including 193 superior bedrooms, deluxe rooms and suites. BT Openzone wireless internet access is available in every area of the hotel.

Package:	Please Tick	Register and pay by 8th February***	Register and pay by 14th March***	Register and pay by 11th April***	Standard Price
<b>All Inclusive GOLD PACKAGE</b> for first 20 registrants before 14th March Conference + Focus Day + Workshop	<input type="checkbox"/>	<b>Save £1000</b> £1597 + VAT*	<b>Save £800</b> £1797 + VAT*	Package not available	£2597 + VAT*
<b>Gold Package</b> Conference + Focus Day + Workshop	<input type="checkbox"/>	<b>Save £500</b> £2097 + VAT*	<b>Save £400</b> £2197 + VAT*	<b>Save £300</b> £2297 + VAT*	£2597 + VAT*
<b>Silver Package</b> Conference + Focus Day	<input type="checkbox"/>	<b>Save £400</b> £1798 + VAT*	<b>Save £300</b> £1898 + VAT*	<b>Save £200</b> £1998 + VAT*	£2198 + VAT*
<b>Conference only</b>	<input type="checkbox"/>	<b>Save £300</b> £1099 + VAT*	<b>Save £200</b> £1199 + VAT*	<b>Save £100</b> £1299 + VAT*	£1399 + VAT*
<b>CEE Countries**</b>	<input type="checkbox"/>	£999 + VAT*	£999 + VAT*	£999 + VAT*	£999 + VAT*

Focus Day Only (if booked separately): £799

Workshop Only (if booked individually): £399

Academic and non-profit discount of 50% available

\* UK VAT is charged at 17.5% and will be assessed and added to the total amount due. UK VAT registration no. GB 799 2259 67

\*\*Only one discount is applicable per person. In order to qualify for discounts, bookings must be received with payment by the early bird dates.

\*\*Central and Eastern European Countries :Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russia, Slovakia, Slovenia, Ukraine, Yugoslavia, Serbia and Montenegro, Turkey, Macedonia, Georgia, Kazakistan, Moldova, Uzbekistan

## Delegate Information

**DELEGATE 1**  Mr  Mrs  Miss  Ms  Dr  Other

First Name \_\_\_\_\_

Family Name \_\_\_\_\_

Position \_\_\_\_\_

Email \_\_\_\_\_

Organisation \_\_\_\_\_

Address \_\_\_\_\_

Phone \_\_\_\_\_

Fax \_\_\_\_\_

## Cancellations & Substitutions

**PAYMENT** is due in full upon completion and return of the registration form. Due to limited conference space we advise early registration and payment by credit card to avoid disappointment. Your registration will not be confirmed until payment is received. Admission to the conference will be refused if payment has not been received.

**CANCELLATION AND SUBSTITUTION POLICY** Provided the fee has been paid in full, substitutions at no extra charge can be made up to 7 business days before the start of the conference. Cancellations must be received in writing or by fax to +44 (0)20 7368 9301, more than 7 days before the conference is to be held in order to obtain a full credit for any future conference. Cancellations received 7

days or less (including the seventh day) prior to the conference will not be credited. In the event that IQPC cancels an event payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IQPC, a rescheduled date. Credit notes remain valid for twelve months. IQPC reserves the right to postpone or cancel an event, to change the location of an event or to alter the advertised speakers for an event. IQPC is not responsible for any loss or damage as a result of substitution, alteration, postponement, or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism, or

hostilities.

**SPEAKER CHANGES** Occasionally it is necessary for reasons beyond our control to alter the content and timing of the programme or the identity of the speakers

**DATA PROTECTION** Personal data is gathered in accordance with the Data Protection Act 1998. Your details may be passed to other companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box below.

Please do not pass my information to any third party

© IQPC Ltd. 2007 UK VAT registration no. GB 799 2259 67

## Payment Methods

Total Price for your Organisation: \_\_\_\_\_

(Add total of all individuals attending): \_\_\_\_\_

Card Number:  VISA  M/C  AMEX

\_\_\_\_\_

Exp. Date:     Sec:

Name On Card: \_\_\_\_\_

Signature: \_\_\_\_\_

Billing Address (if Different From below): \_\_\_\_\_

City/Country/Postcode \_\_\_\_\_

Cheque enclosed for: £ \_\_\_\_\_  
(Made payable to IQPC Ltd.)

**By Direct Transfer:** By Bank Transfer (please quote with remittance advice) IQPC Bank details: HSBC Bank; Sort Code: 40 38 18 Account No: 51304143 Swift Code: MIDLGB2112V. IBAN Code: GB59 MIDL 4038 1851 3041 43 Account name: International Quality and Productivity Centre Ltd. Ref: Please include name of the attendee(s) and the number: EL11314.02

## Digital Conference on CD ROM

A digital version of the conference proceedings, including all the presentations in audio format

"An excellent service, an invaluable reference tool, easy to access and easy to store - all in all a top product"

Recent digital conferences available - £599 plus VAT each

**Polymorphism and Crystallisation** (March 2008)

**Lead-Finding Screening** (May 2008)

**Drug Discovery Automation** (November 2007)

Please send me conference materials indicated above.

I have filled out credit card details above

For further information please call: 0207 368 9300

or email: [knowledgebank@iqpc.co.uk](mailto:knowledgebank@iqpc.co.uk)

To search IQPC's archived conference documentation, visit: [www.iqpcknowledgebank.com](http://www.iqpcknowledgebank.com)

Your order is risk free! If you are not happy with the content, simply return the products to us within seven days for a full refund.